Table 1.
Subjects' baseline and demographic characteristics
| Demographic characteristic | Ponezumab |
Placebo A |
Ponezumab |
Placebo B |
|||
|---|---|---|---|---|---|---|---|
| 0.1 mg/kg |
0.5 mg/kg |
1.0 mg/kg |
3.0 mg/kg |
8.5 mg/kg |
|||
| n = 25 | n = 25 | n = 25 | n = 24 | n = 32 | n = 31 | n = 32 | |
| Gender, n | |||||||
| Male | 13 | 10 | 14 | 11 | 12 | 14 | 15 |
| Female | 12 | 15 | 11 | 13 | 20 | 17 | 17 |
| Mean (SD) age, years | 70.8 (8.2) | 71.9 (9.4) | 72.2 (8.4) | 70.0 (7.8) | 70.5 (8.9) | 71.8 (7.3) | 70.4 (10.3) |
| Race, n | |||||||
| White | 16 | 17 | 19 | 17 | 23 | 21 | 25 |
| Black | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Asian | 9 | 8 | 6 | 6 | 7 | 9 | 7 |
| Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Mean (SD) years of education | 12.4 (3.5) | 12.2 (4.7) | 11.7 (4.2) | 12.1 (3.3) | 12.4 (3.6) | 12.2 (4.2) | 13.7 (4.0) |
| Mean (SD) screening MMSE | 21.5 (2.9) | 21.4 (3.6) | 20.8 (3.0) | 21.0 (3.4) | 22.5 (2.5) | 20.9 (3.1) | 21.9 (3.4) |
| Mean (SD) baseline ADAS-Cog | 20.0 (7.9) | 20.4 (8.2) | 20.8 (6.1) | 20.0 (7.0) | 19.4 (7.0) | 24.5 (10.1) | 18.4 (7.5) |
Abbreviations: SD, standard deviation; MMSE, Mini–Mental State Examination; ADAS-Cog, Alzheimer's Disease Assessment Scale–Cognitive Subscale.